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able in this large Medicaid cohort. Patients who used buprenorphine persistently 
for 12 months had lower risk of all-cause hospitalizations and ED visits than those 
experiencing early discontinuation.
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OBJECTIVES: Clinical guidelines for schizophrenia recommend monotherapy of 
second-generation antipsychotics (SGAs) for treating patients suffering from schizo-
phrenia, but do not address the issue of how to treat patients with inadequate first-
line treatment. The aim of this study is to describe real-word prescription patterns 
for patients suffering from schizophrenia in Japan. METHODS: Using data from the 
Japan Medical Data Center (JMDC) database, a retrospective longitudinal cohort study 
was conducted, including adults aged from 18 to 65 years with a first prescription of 
antipsychotic (index date) between January 2009 and September 2013, and diagnosed 
with schizophrenia around index date. The treatments prescribed in first and second 
lines were described and treatment duration was estimated using the Kaplan-Meier 
method. Proportions of patients receiving an add-on treatment, switching or not 
treated after discontinuation of first-line treatment were estimated. RESULTS: 1,674 
patients were included. Mean age of the population was 35.4±11.2 years at index 
date and 54.5% were females. 82% of these patients received SGA monotherapy as 
first-line therapy. Among this subgroup, the most frequently prescribed drugs were: 
olanzapine (27.1%), aripiprazole (27.0%), risperidone (22.1%) and quetiapine (16.3%). 
64% of patients reached end of first-line treatment within 6 months, of whom 26.6% 
had a switch, 11.6% had an augmentation and 61.8% stopped treatment. The median 
duration of first-line treatment was 3 months. Most frequently prescribed therapies 
in second line were aripiprazole (23.2%), olanzapine (22.5%), quetiapine (13.7%) and 
risperidone (9.1%), and 6.3% were antipsychotic combinations. CONCLUSIONS: SGA 
monotherapy was frequently prescribed as first-line treatment, consistently with 
clinical guidelines. However the duration of first-line therapy is short and the high 
proportion of patients without treatment may be a cause for concern.
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OBJECTIVES: To examine the risk of hospitalization due to cardiovascular events 
associated with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors, compared to 
other anti-diabetic agents, among diabetic patients. METHODS: Patients age > 18 
years and taking diabetes medication were identified in the IMS Lifelink Plus® 
database for the years 2006-2013. Cardiovascular events were defined as inpatient 
discharge diagnosis of heart failure, stroke and coronary heart disease occurring at 
least 30 days after initiation of therapy. Patients were continuously enrolled for 6 
months prior and 24 months post the date of first antidiabetic prescription (‘index-
date’). Patients with cardiovascular event in 6-month pre-index period were excluded. 
Patients were followed for 24 months post index-date. Patients with at-least 30 days 
of DPP-4 inhibitors as their starting therapy were identified as DPP-4 inhibitors users, 
while patients with at-least 30 days of any other anti-diabetic therapy and no DPP-4 
inhibitors in the 24-month follow-up period were identified as other anti-diabetic 
users. Unadjusted and adjusted logistic regression models were employed to esti-
mate the risk of cardiovascular-related hospitalizations for those on DPP-4 inhibi-
tors, compared with those on other antidiabetic agents. The model was adjusted for 
demographics, comorbidities, and region of residence. RESULTS: The final sample 
consisted of 45,767 patients with mean age of 50.71 years and 55.15 % females. Of 
these, 1973 patients had DPP-4 inhibitors while 43,794 had other anti-diabetic therapy. 
At baseline 2.43% patients had hypertension, 36.06% had dyslipidemia and 28.63% 
had valve disorder. Patients taking DPP-4 inhibitors had an increased risk for having 
a cardiovascular event as compared with those on other anti-diabetic agents (unad-
justed odds ratio:1.524, 95% confidence interval [CI]:1.131-2.056; adjusted odds ratio: 
1.331, 95% CI: 0.985-1.799). CONCLUSIONS: DPP4 inhibitors may increase the risk of 
cardiovascular events as compared to other anti-diabetic agents, which warrants 
close monitoring of diabetic patients on DPP-4 inhibitors.
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OBJECTIVES: To examine the incidence of different types of adverse drug 
reactions(ADR) in a group of drug treated hypertensive patients. METHODS: This 
is a cross sectional study conducted in collaboration with Department of Internal 
Medicine, College of Medical Sciences and Teaching Hospital, Bharatpur, Chitwan 
during the period of three months (1st July to 30th September 2014). The patients 
attending the outpatient department of Cardiology and under antihypertensive 
drugs therapy were taken as sample. RESULTS: Among the total 100 patients stud-
ied, the mean age was 58.56 ± 12.83 years. Males contributed to 59 and females 41 
OBJECTIVES: This study aims to explore physician care-providing behavior in 
treating children and adolescents with Attention-deficit/hyperactivity disorder 
(ADHD). METHODS: The study was conducted using the GE electronic medical 
records (GE-EMR) 1995-2010. The cohort consisted of all children and adolescents 
(age≤ 18 years), who were prescribed either stimulants or atomoxetine hydrochloride 
and had at least two physician visits. Incident ADHD cases, defined as those who 
have not been diagnosed with ADHD or received ADHD prescription in the last 6 
months, were followed for a period of 12 months to observe their physician care-
providing behavior. RESULTS: Approximately 5% of children in the GE-EMR were 
diagnosed with ADHD. 74% of the cases were identified by primary care physicians 
(PCPs), 5% by a mental health specialist, and the remaining cases had missing pro-
vider specialties. 52% (N= 101,516) of ADHD cases were prescribed pharmacotherapy 
immediately following the first ADHD diagnosis, while 43% (N= 35,069) had delayed 
prescriptions with median time to treatment of 55 days (IQR: (21-171 days)). ADHD 
cases first identified by PCPs were more likely to receive immediate pharmaco-
therapy than those identified by mental health specialists (58% vs 41%, P= < 0.0001). 
The majority of the children who received pharmacotherapy were prescribed stimu-
lants (89%), about 10% were prescribed atomoxetine and less than 1% were on a 
combination of the two. The most commonly prescribed concurrent non-ADHD 
medications were antidepressants (11%) and atypical antipsychotics (4.6%). During 
the one year follow-up, children with ADHD had an average of six office visits with 
the first follow-up visit at an average of 51 days after treatment initiation. Only 
0.39% (N= 318) of children received concurrent psychotherapy. CONCLUSIONS: As 
compared to mental health specialists, PCPs are more likely to prescribe pharmaco-
therapy immediately after the ADHD cases were identified. Medication concurrent 
psychotherapy is low in patients seen by either PCPs or mental health specialists.
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OBJECTIVES: Little evidence exists to support the increasing concurrent use of mul-
tiple antipsychotics (APs) among children. Case reports suggest that use of multiple 
APs could lead to an increased risk of delirium, serious behavioral changes, cardiac 
arrhythmias, and death. In 2013, the National Collaborative for Innovation in Quality 
Measurement (NCINQ) proposed a quality measure of concurrent use of multiple 
(2+) APs among children for use in Medicaid and CHIP programs. The Pharmacy 
Quality Alliance (PQA) has been working on a similar measure using 3+ APs. The 
objectives were to analyze the performance in the Mississippi Medicaid program on 
both the 2+ and 3+ proposed quality measures. METHODS: A retrospective analysis 
was conducted using Mississippi Medicaid data for July 2013 through June 2014. For 
both measures the denominator contained beneficiaries ages 0 to 21 as of June 2014, 
who were continuously enrolled 3+ months and were on any AP for at least 90 days. 
The numerators contained those beneficiaries who were concurrently on 2+ APs or 
3+ APs for a period of at least 90 days during the measurement year. RESULTS: The 
denominator included 4,435 children who were on at least 1 AP. About 464 (10.5%) 
and 159 (3.6%) beneficiaries were concurrently on 2+ or 3+ APs respectively. The 
performance rates on the two measures did not significantly differ for the fee-for-
service or two managed care plans. Also, the performance rates on the measures 
decreased with an increase in beneficiary age. These results also were consistent 
across the three health plans. CONCLUSIONS: There is considerable debate about 
the rate of appropriate concurrent use of 2+ APs in this population. However, there is 
no clinical support for concurrent use of 3+ APs. Although the percentage of children 
concurrently taking 3+ APs is small, possible drug utilization management actions 
are needed to further reduce this occurrence.
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OBJECTIVES: Buprenorphine is an effective treatment for opioid use disorders. 
However, uncertainty about optimal duration of buprenorphine treatment may 
lead to substantial variation in provider decision-making, and patient outcomes. In 
response to the high cost of treatment, some payers have placed limits on treatment 
duration although little is known about the impact of these limits. We used group-
based trajectory models to identify distinct trajectories of buprenorphine use based 
on prescription refills, and examined emergency department (ED) and inpatient use 
associated with these trajectories in a large state Medicaid program. METHODS: 
We analyzed data from a retrospective cohort study of 10,945 adults (18-64 years) 
Pennsylvania Medicaid enrollees initiating a new episode of buprenorphine treat-
ment between 2007-2011. We used group-based trajectory models to identify tra-
jectories in the 12 months following buprenorphine initiation. Multivariate Cox 
proportional hazard models were used to examine the association between tra-
jectories and time to first all-cause hospitalization and first emergency depart-
ment (ED) visit in the following year. RESULTS: Six trajectories of buprenorphine 
treatment were identified: 4 groups discontinued buprenorphine (24.9% discon-
tinued < 3 months, 18.7% at 3-5 months, 12.4% at 5-8 months, 13.3% > 8 months); 
9.5% refilled intermittently; and 21.2% refilled persistently for 12 months. Factors 
associated with treatment discontinuation were minority race, having history of 
frequent ED visits and hospitalizations, and comorbid psychoses. After adjusting 
for sociodemographics, health status, and provider-level covariates, patients who 
refilled persistently had a 20% lower risk of all-cause hospitalizations (hazard ratio 
[HR]= 0.80, 95% CI, 0.68-0.94) and 15% lower risk of an ED visit (HR= 0.85, 95% CI, 
0.77-0.94) in the subsequent year, compared to those discontinuing between 3-5 
months. CONCLUSIONS: Buprenorphine treatment trajectories were highly vari-
